tenapanor (Ibsrela)
Jump to navigation
Jump to search
Indications
- irritable bowel syndrome with constipation
- control of serum phosphorus levels in adults with chronic kidney disease on dialysis, as a single agent or in combination with phosphate binder
Dosage
Tabs: 50 mg
Adverse effects
Mechanism of action
- inhibits sodium-hydrogen exchanger NHE3 in the GI tract
More general terms
References
- ↑ RxNorm
- ↑ Brooks M FDA OKs Tenapanor (Ibsrela) for IBS With Constipation in Adult Medscape - Sep 12, 2019. https://www.medscape.com/viewarticle/918341
- ↑ Wikipedia: Tenapanor https://en.wikipedia.org/wiki/Tenapanor
- ↑ Kuznar W FDA Panel Endorses Kidney Disease Drug for Serum Phosphorus Control. Advisors see need for alternatives, citing suboptimal efficacy and tolerance of approved options. MedPage Today. November 17, 2022 https://www.medpagetoday.com/nephrology/generalnephrology/101802
- ↑ Lembo AJ, Chey WD, Harris LA et al. Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis. Am J Gastroenterol. 2024 Mar 15 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38294158 https://journals.lww.com/ajg/fulltext/9900/abdominal_symptom_improvement_during_clinical.1000.aspx